Sangamo BioSciences | SGMO - Assets


Sangamo BioSciences reported $97.56M in Assets for its fiscal quarter ending in June of 2025.





Assets Change Date
Alaunos Therapeutics USD 3.72M 1.01M Sep/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Bayer EUR 104.54B 331M Dec/2025
BioCryst Pharmaceuticals USD 514.16M 67.73M Dec/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Cipla INR 401.64B 27.77B Sep/2025
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 156.57M 58.73M Dec/2025
CSL USD 37.9B 1.5B Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Grifols EUR 23.15B 142.7M Dec/2025
Ionis Pharmaceuticals USD 3.52B 490.91M Dec/2025
J&J USD 199.21B 6.39B Dec/2025
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Novartis USD 110.95B 3.66B Dec/2025
Omeros USD 200.57M 34.59M Jun/2025
Pfizer USD 208.73B 2.64B Sep/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
Tectonic Therapeutic USD 261.04M 15.96M Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025